newsfilter
← Latest News
GlobeNewswire·

NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates

Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003 Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated in the second half of 2021